KCRS25 Presentations & Video
Program content is now LIVE!
The program slide presentations are available now and can be viewed by clicking the icon to the left of the title. Each video is the full session length; to jump to a particular presentation, note the timestamp in red beneath the speaker’s name.
Thursday, July 17th
Click the icon next to the presentation to view slides
PRE-MEETING:
Variant Kidney Cancers: Bridging Biology to Breakthroughs
SESSION ONE:
Biology and Therapeutic Vulnerabilities: Needs and Opportunities
Variant 1: Papillary
Bradley McGregor, Dana-Farber Cancer Institute
(Video presentation begins at 7:54)
Variant 2: Chromophobe
Elizabeth Henske, Brigham and Women’s Hospital/Harvard Medical School
(Video presentation begins at 18:54)
Variant 3: Translocation
Srinivas Viswanathan, Dana-Farber Cancer Institute
(Video presentation begins at 28:49)
Variant 4: Unclassified
Yingbei Chen, Memorial Sloan Kettering Cancer Center
(Video presentation begins at 41:40)
SESSION TWO:
Clinical Trial Design and Execution
Lessons Learned from Other Cancers
Vivek Subbiah, Sarah Cannon Research Institute
Statistical Approaches for Designing and Conducting Rare Subtype Trials
Wanling Xie, Dana-Farber Cancer Institute
(Video presentation begins at 0:00)
Regulatory Considerations and Endpoints for Rare Subtype Trials
Chana Weinstock, U.S. Food and Drug Administration
Patient Advocacy, Registry, and Trial Recruitment: What Has Worked in Rare Cancers
Joshua Mann, VHL Alliance
(Video presentation begins at 11:10)
Industry Support of Rare Subtype Trials
Sumanta Pal, City of Hope Comprehensive Cancer Center
(Video presentation begins at 17:52)
SESSION ONE
SESSION TWO
Keynote
Leading the Way in Fostering Early Careers with a Focus on Kidney Cancer
W. Kimryn Rathmell
The Ohio State University Comprehensive Cancer Center
Keynote Presentation
Session 1
From Federal Funding to Patient Impact: Kidney Cancer Research That Delivers
Moderated by
Eric Jonasch, MD Anderson Cancer Center
Cheryl Walker, Baylor College of Medicine
Building the Infrastructure for Discovery: A Clinical Trial Consortium to Accelerate Kidney Cancer Research
Eric Jonasch, MD Anderson Cancer Center
(Video presentation begins at 2:45)
Personalized Vaccines in Kidney Cancer: A Journey from Concept to Clinic
David Braun, Yale School of Medicine
(Video presentation begins at 9:59)
Targeting Ferroptosis in Clear Cell RCC: Translating KCRP Discoveries into the Clinic
Mei Koh, University of Utah
(Video presentation begins at 23:09)
From Bench to Bedside: Advancing KIM-1 as a Tool for Clinical Decision-Making
Wenxin (Vincent) Xu, Dana-Farber Cancer Institute
(Video presentation begins at 34:10)
Redesigning CAR-T for Solid Tumors: A New Path Toward Cures for Kidney Cancer
Wayne Marasco, Dana-Farber Cancer Institute
(Video presentation begins at 44:17)
Session 2
Charting the Next Frontier: Genetic Evaluation and Screening for Early Detection of Kidney Cancer
Moderated by
Michael Serzan, Dana-Farber Cancer Institute
Samantha Greenberg, UT Southwestern Medical Center
The State of Screening Individuals with a Hereditary Risk of Kidney Cancer
Maria Carlo, Memorial Sloan Kettering Cancer Center
(Video presentation begins at 1:26)
Novel Imaging Approaches for Early Detection of Kidney Cancer
Mark Ball, National Cancer Institute
(Video presentation begins at 13:39)
A Genetic Perspective: Optimizing Screening for Individuals with Negative Germline Testing
Lindsey Byrne, The Ohio State University Comprehensive Cancer Center
(Video presentation begins at 28:03)
Risk Stratified Screening for Kidney Cancer
Grant Stewart, University of Cambridge
(Video presentation begins at 42:50)
Session 3
Trials in Progress
Moderated by
Robert Motzer, Memorial Sloan Kettering Cancer Center
Thai Ho, Medical University of South Carolina
Phase II Trial of Ivonescimab in Patients with Advanced Clear Cell Renal Cell Carcinoma Previously Treated with Immune Checkpoint Blockade: IVORY Trial (NCT06940518)
Nazli Dizman, MD Anderson Cancer Center
(Video presentation begins at 1:19)
A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of First-in-Class XmAb819 (ENPP3 x CD3) in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma (ccRCC) (NCT05433142)
Ritesh Kotecha, Memorial Sloan Kettering Cancer Center
(Video presentation begins at 6:09)
Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma – STRIKE! (A033201) – (NCT06661720)
Bradley McGregor, Dana-Farber Cancer Institute
(Video presentation begins at 8:48)
LASER – a Phase 2 trial of 177Lu-PSMA-617 as Systemic Therapy for Renal Cell Carcinoma (NCT06964958)
Praful Ravi, Dana-Farber Cancer Institute
(Video presentation begins at 12:14)
EXACT: A Randomized Phase II Trial of XL092 (Zanzalintinib) in Combination with Immunotherapy in Patients who Progress on Adjuvant Therapy in Clear Cell RCC (NCT06863311)
Karie Runcie, Columbia University Irving Medical Center
(Video presentation begins at 16:12)
A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Patients with Renal Cell Carcinoma or Urothelial Carcinoma (NCT06318871)
Wenxin (Vincent) Xu, Dana-Farber Cancer Institute
(Video presentation begins at 19:14)
Session 4
Rapid Oral Abstract Presentations
Moderated by
Sumanta Pal, City of Hope Comprehensive Cancer Center
Kelly Fitzgerald, University of California, San Francisco
Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Belzutifan Versus Everolimus in Previously Treated Advanced Renal Cell Carcinoma (RCC): LITESPARK-005 (LS-005)
Thomas Powles, Barts Cancer Center
(Video presentation begins at 0:33)
Exploring Health-Related Quality of Life Across the Disease Spectrum in Renal Cell Carcinoma: A Conceptual Domain Analysis
Koral Shah, City of Hope Comprehensive Cancer Center
(Video presentation begins at 6:11)
Phase 2 Trial of Metastasis Directed Radiotherapy Without Systemic Therapy (MRWS) for Oligometastatic Clear Cell Renal Cell Carcinoma (ccRCC) and Investigation of Circulating Tumor DNA (ctDNA)
Chad Tang, MD Anderson Cancer Center
(Video presentation begins at 10:11)
The Actionable Microbial Gut Checkpoint MAdCAM-1 in Patients with Advanced Renal Cell Carcinoma
Carolina Alves Costa Silva, Institut Gustave Roussy
(Video presentation begins at 14:58)
Characterizing Carbonic Anhydrase 9 and HIF-2α RNA Expression in Clear Cell Renal Cell Carcinoma (ccRCC)
Yu-Wei Chen, University of California, San Diego
(Video presentation begins at 18:36)
Influence of Sex on Immunosurveillance and Metastatic Tropism in Novel Mouse Models of Clear Cell Renal Cell Carcinoma
Doris Zheng, Memorial Sloan Kettering Cancer Center
(Video presentation begins at 35:51)
Evaluating Global Disparities in Clinical Trial Availability for Renal Cell Carcinoma
Ruchi Agarwal, University of Pennsylvania
(Video presentation begins at 42:42)
Investigating the Mechanisms of Neoadjuvant Olaparib and Cediranib in Renal Cancer: Results of Arms 1 to 3 of the WIndow of Opportunity in REnal cancer (WIRE) Clinical Trial
James Jones, University of Cambridge
(Video presentation begins at 47:08)
Real-World Evidence Shows No Survival Advantage with Contemporary First-Line Strategies in Papillary Renal Cell Carcinoma: A Call for Randomized Trials
Miguel Zugman, City of Hope Comprehensive Cancer Center
(Video presentation begins at 52:00)
Friday, July 18th
Founding Partner Presentation
The Road to Non-Clear Cell RCC
Jose Perez Torrealba, Exelixis
Click the icon next to the presentation to view slides
Session 5
Clinical and Scientific Updates in Kidney Cancer
Moderated by
Toni Choueiri, Dana-Farber Cancer Institute
Front Line Systemic Therapy Strategies
David McDermott, Beth Israel Deaconess Medical Center
(Video presentation begins at 0:56)
Subsequent Line Treatments for Advanced Disease
Robert Motzer, Memorial Sloan Kettering Cancer Center
(Video presentation begins at 15:12)
Adjuvant Treatment Options
Naomi Haas, Abramson Cancer Center
(Video presentation begins at 30:50)
Strategies for Patients with Rare Subtypes
Mehmet Bilen, Emory Winship Cancer Institute
(Video presentation begins at 43:31)
Novel Therapies Outside Immunotherapy
Thai Ho, Medical University of South Carolina
(Video presentation begins at 56:17)
Essential Biomarkers in RCC
Wenxin (Vincent) Xu, Dana-Farber Cancer Institute
(Video presentation begins at 1:08:04)
Session 6
From Concept to Clinic: The Emerging Role of Precision Immunotherapy in Kidney Cancer
Moderated by
Hans Hammers, UT Southwestern Medical Center
David Braun, Yale School of Medicine
Engaging Native Immunity through ENPP3
Charles Drake, Johnson & Johnson
(Video presentation begins at 1:11)
Novel Targets for Cellular Therapies in RCC
Rosa Nadal Rios, Fred Hutchinson Cancer Center
(Video presentation begins at 18:28)
Next Generation T-Cell Engineering
Sidi Chen, Yale School of Medicine
(Video presentation begins at 36:50)
Future of Cancer Vaccines
Patrick Ott, Dana-Farber Cancer Institute
(Video presentation begins at 50:49)
Session 7
Oral Abstract Presentations
Moderated by
Rana McKay, University of California, San Diego
Wesley Yip, City of Hope Comprehensive Cancer Center
Combination Casdatifan plus Cabozantinib in Previously Treated Patients with Clear Cell Renal Cell Carcinoma: Results from an Expansion Cohort of ARC-20 (NCT05536141)
Toni Choueiri, Dana-Farber Cancer Institute
(Video presentation begins at 1:18)
Pembrolizumab Plus Lenvatinib for Previously Untreated Advanced Non–Clear Cell Renal Cell Carcinoma: 3-Year Follow-up of the Phase 2 KEYNOTE-B61 Study
Laurence Albiges, Institut Gustave Roussy
(Video presentation begins at 14:45)
CD163⁺ Tumor-Associated Macrophages and Clinical Outcomes to First-Line Nivolumab Therapy in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Insights from the HCRN GU16-260 Trial
Berkay Simsek, Brigham and Women’s Hospital
(Video presentation begins at 29:20)
Integrative Clinical, Genomic, Transcriptomic, and Immunopathologic Characterization of Circulating KIM-1 in Metastatic RCC
Marc Machaalani, Dana-Farber Cancer Institute
(Video presentation begins at 36:53)
Lower Checkpoint Gene Expression is Associated with Primary Resistance to Nivolumab-Ipilimumab Combination in Advanced Renal Cell Carcinoma
Rana McKay, University of California, San Diego
(Video presentation begins at 43:03)
Derepression of Human Endogenous Retroviruses in ccRCC: Implications for Immunotherapy
Qinqin Jiang, Dana-Farber Cancer Institute
(Video presentation begins at 50:14)
Session 8
Biotech Showcase
Moderated by
Thomas Powles, Barts Cancer Centre
David McDermott, Beth Israel Deaconess Medical Center
At the PEAK of ccRCC, HIF2a Drug Development eVOLVEs – Casdatifan Initiating Phase 3 Trials
Jonathan Yingling, Arcus Biosciences
(Video presentation begins at 0:06)
Overcoming Innate and Adaptive Resistance in RCC: Combination with the Next-Generation Farnesyl Transferase Inhibitor, KO-2806, as a Strategy to Enhance VEGF TKI Efficacy
Jabed Seraj, Kura Oncology
(Video presentation begins at 11:20)
Unmasking the Potential of Conditionally-Activated Cytokines: Lessons Learned from the Early Clinical Development of WTX-124, a Tumor-Activated IL-2 INDUKINE Molecule
Randi Isaacs, Werewolf Therapeutics
(Video presentation begins at 19:21)
ITM’s Investigational CAIX-targeted Radiopharmaceuticals for Diagnosis and Treatment of Patients with ccRCC: Ph I/II Trial Design and First-in-Human CAIX Images
Robert Awadallah, ITM Isotope Technologies
(Video presentation begins at 32:22)
Targeting PTPN2/1 with ABV-CLS-484 as a Novel Immunotherapeutic Approach for Treating Cancer
Jonathan Powell, Calico Labs
(Video presentation begins at 44:47)
Natera’s Portfolio for Ultrasensitive Molecular Residual Disease (MRD) Detection
Minetta Liu, Natera
(Video presentation begins at 57:23)
Comprehensive Molecular Testing for Solid Tumors
Brian Liu, Caris Life Sciences
(Video presentation begins at 1:13:33)
